Global Castration-Resistant Prostate Cancer (CRPC) Market Size To Exceed USD 25.45 Billion by 2035| CAGR of 9.10% : Market Statistics Report

• As per Spherical Insights & Consulting, The Global Castration-Resistant Prostate Cancer (CRPC) Market Size is expected To Grow from USD 10.65 Billion in 2024 to USD 25.45 Billion by 2035, at a CAGR of 9.10% during the forecast period 2025-2035, owing to the launch of new therapies in the market and the rise in the number of cases.

 

• The leading Castration-Resistant Prostate Cancer (CRPC) Market Companies such as Astellas Pharma, Janssen Pharmaceuticals, Pfizer, Novartis, Bayer, Bristol-Myers Squibb, Sanofi, Amgen, Roche, AstraZeneca, Merck & Co., Dendreon Pharmaceuticals, Clovis Oncology, Ipsen, Exelixis, and Others.

 

 

Castration-Resistant Prostate Cancer (CRPC) Treatment Market: Understanding and Treatment Algorithm:

Castration-Resistant Prostate Cancer (CRPC) is an advanced form of prostate cancer that continues to grow despite low testosterone levels achieved through hormone therapy. It is characterized by disease progression despite androgen deprivation, often leading to metastasis. CRPC is challenging to treat and requires targeted therapies to manage symptoms and slow cancer growth.

 

Castration-Resistant Prostate Cancer (CRPC) Diagnosis:

Diagnosis involves monitoring prostate-specific antigen (PSA) levels, imaging tests like bone scans, CT, or MRI to detect metastasis, and assessing symptoms despite ongoing androgen deprivation therapy. Rising PSA levels or new lesions indicate progression, confirming resistance to castration and guiding further treatment decisions.

 

Castration-Resistant Prostate Cancer (CRPC) Treatment

Treatment for Castration-Resistant Prostate Cancer (CRPC) includes androgen receptor inhibitors like enzalutamide and apalutamide, chemotherapy agents such as docetaxel, immunotherapy (e.g., sipuleucel-T), targeted therapies like PARP inhibitors, and radiopharmaceuticals such as radium-223. Treatment choice depends on disease progression, metastasis, patient health, and prior therapies to manage symptoms and prolong survival.

 

Castration-Resistant Prostate Cancer (CRPC) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Castration-Resistant Prostate Cancer (CRPC), Gender-specific Diagnosed Incidence of Castration-Resistant Prostate Cancer (CRPC), Type-specific Diagnosed Incidence of Castration-Resistant Prostate Cancer (CRPC), Age-specific Diagnosed Incidence of Castration-Resistant Prostate Cancer (CRPC), Diagnosed Incident Population based on Primary Site of Castration-Resistant Prostate Cancer (CRPC), and Diagnosed Incident Population based on Histologic Classification of Castration-Resistant Prostate Cancer (CRPC) Tumour in the global market covering North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa from 2024 to 2035.

 

Principal Insights

This section offers a global overview of castration-resistant prostate cancer (CRPC) epidemiology in major markets worldwide.

 

Country-Wise- Castration-Resistant Prostate Cancer (CRPC) Multiforme Epidemiology

• The epidemiology segment provides Castration-Resistant Prostate Cancer (CRPC) prevalence data and findings across key regions worldwide, including North America, Europe (Germany, France, Italy, Spain, and the United Kingdom), Asia-Pacific (including Japan), Latin America, the Middle East, and Africa.

 

Castration-Resistant Prostate Cancer (CRPC) Recent Developments:

• In June 2023, Pfizer announced that the U.S. FDA approved TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). This approval was based on the Phase 3 TALAPRO-2 trial, which demonstrated a 55% reduction in the risk of disease progression or death in patients treated with the combination compared to those receiving XTANDI alone.

 

Castration-Resistant Prostate Cancer (CRPC) Marketed Drugs:

• Xtandi: Astellas Pharma

Xtandi (enzalutamide) is an androgen receptor inhibitor that blocks the effects of androgens, promoting prostate cancer growth. It is FDA-approved for non-metastatic and metastatic CRPC, improving survival and delaying disease progression.

 

• Zytiga: Janssen Pharmaceuticals

Zytiga (abiraterone acetate) inhibits androgen biosynthesis, reducing testosterone production. It is used in metastatic CRPC patients, often combined with prednisone, to extend survival.

 

• Jevtana: Sanofi

Jevtana (cabazitaxel) is a chemotherapy agent used in metastatic CRPC patients previously treated with docetaxel, targeting microtubules to inhibit cancer cell division.

 

Castration-Resistant Prostate Cancer (CRPC): Emerging Therapies

• Relacorilant: Relacorilant is a selective glucocorticoid receptor modulator in clinical trials for CRPC. It aims to improve treatment response by overcoming resistance to androgen receptor-targeted therapies, enhancing effectiveness in advanced disease stages.
• Darolutamide: Darolutamide is a next-generation androgen receptor inhibitor under investigation for improved efficacy and safety in metastatic CRPC, particularly in patients with resistance to existing treatments.
• Olaparib: Olaparib is a PARP inhibitor approved for HRR gene-mutated metastatic CRPC, with ongoing studies exploring broader applications and combination therapies to increase patient benefit.
• Talquetamab: Talquetamab is a bispecific antibody targeting GPRC5D and CD3, currently in early clinical development, designed to activate immune cells and target prostate tumor cells resistant to conventional therapies.

 

Castration-Resistant Prostate Cancer (CRPC) Market Outlook

• The castration-resistant prostate cancer (CRPC) market refers to the global industry involved in the development, manufacturing, and commercialization of drugs and therapies specifically designed to treat prostate cancer that continues to progress despite androgen deprivation therapy. This market includes targeted therapies, immunotherapies, chemotherapy, and combination treatments aimed at managing advanced, treatment-resistant prostate cancer.
• Key drivers of the market include the rising prevalence of advanced prostate cancer globally, increased awareness and early diagnosis, advancements in targeted therapies and immunotherapies, and growing investment in research and development. Additionally, the expanding aging population and improved healthcare infrastructure are accelerating market growth.
• The market offers significant opportunities due to ongoing research in novel therapies, rising adoption of personalized medicine, and expanding indications for existing drugs. Advances in combination therapies and immunotherapies, along with unmet patient needs for effective treatments, also present growth potential in emerging and developed markets.
• Global government initiatives in prostate cancer treatment focus on enhancing early detection, improving access to therapies, and fostering international collaborations to address disparities in care and research.
• Limited access to advanced therapies and late-stage diagnosis remains a major challenge in managing castration-resistant prostate cancer globally.
• The market is projected to grow due to increasing patient prevalence, advancements in targeted therapies, and rising awareness of innovative treatment options.

 

Castration-Resistant Prostate Cancer (CRPC) Market Segmentation

By Therapy Type:

• Hormonal Therapy
• Immunotherapy
• Chemotherapy
• Radiotherapy

 

Hormonal Therapy dominates the Global Castration-Resistant Prostate Cancer market due to its effectiveness in targeting androgen receptors, which play a crucial role in prostate cancer progression. It remains the first-line treatment for most patients, offering improved survival and quality of life. Additionally, ongoing advancements and widespread clinical adoption contribute to its leading market share.

 

By Drug Class:

• Antineoplastic
• Non-steroidal Antiandrogen
• Corticosteroids
• Microtubule Inhibitor
• Others

 

Antineoplastic drugs dominate the Castration-Resistant Prostate Cancer market due to their direct action in inhibiting cancer cell growth and proliferation. Their broad application across various stages of the disease, combined with continuous innovation in chemotherapy and targeted therapies, drives their leading market share compared to other drug classes.

 

Regional Segment Analysis of the Castration-Resistant Prostate Cancer (CRPC) Market

North America dominates the Castration-Resistant Prostate Cancer (CRPC) market, accounting for the largest share globally. This is driven by advanced healthcare infrastructure, widespread availability of innovative therapies, high patient awareness, and robust screening programs leading to early diagnosis. Additionally, strong government support, favourable reimbursement policies, and substantial investments in R&D by key pharmaceutical companies further strengthen market leadership. The U.S. is a major contributor due to extensive clinical trials and rapid adoption of cutting-edge treatments.

 

The Asia-Pacific region is experiencing the fastest growth in the CRPC market. Factors fueling this growth include rising healthcare expenditure, expanding healthcare infrastructure, increasing awareness about prostate cancer, and growing demand for advanced treatment options. Emerging economies like China, India, Japan, and South Korea are witnessing improvements in diagnostic capabilities and access to novel therapies. Moreover, government initiatives to enhance cancer care, coupled with a large patient pool and growing clinical research activities, are accelerating market expansion in this region.

 

Castration-Resistant Prostate Cancer (CRPC) Market Key Companies

• Astellas Pharma
• Janssen Pharmaceuticals
• Pfizer
• Novartis
• Bayer
• Bristol-Myers Squibb
• Sanofi
• Amgen
• Roche
• AstraZeneca
• Merck & Co.
• Dendreon Pharmaceuticals
• Clovis Oncology
• Ipsen
• Exelixis
• Others

 

Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Report Scope

• The Castration-Resistant Prostate Cancer (CRPC) therapeutics market report provides a detailed overview, covering its causes, symptoms, disease progression, and existing treatment options.
• Detailed insights into Castration-Resistant Prostate Cancer (CRPC)’s epidemiology and therapeutic approaches are included.
• Additionally, a comprehensive review of existing and emerging Castration-Resistant Prostate Cancer (CRPC) therapies is provided, including an evaluation of new treatments expected to influence the current Castration-Resistant Prostate Cancer (CRPC) treatment market landscape.
• The report includes a detailed review of the Castration-Resistant Prostate Cancer (CRPC) therapeutics market, both historical and forecasted, highlighting the global drug reach.
• The Patient-Based Castration-Resistant Prostate Cancer (CRPC) Market Forecasting report offers valuable insights into trends shaping the global Castration-Resistant Prostate Cancer (CRPC) market, helping to develop effective business strategies.

 

Castration-Resistant Prostate Cancer (CRPC) Treatment Market Report Insights

• Forecasting Market Trends Based on Patient Data and Disease Rates
• Castration-Resistant Prostate Cancer (CRPC) Therapeutic Approaches in Castration-Resistant Prostate Cancer (CRPC)
• Review Of Drugs in Development for Castration-Resistant Prostate Cancer (CRPC)
• Market, Growth, and Trends in Castration-Resistant Prostate Cancer (CRPC)
• Market Opportunities in Castration-Resistant Prostate Cancer (CRPC) Treatment
• Effects Of Future Therapies on Castration-Resistant Prostate Cancer (CRPC) Treatment.

 

Castration-Resistant Prostate Cancer (CRPC) Treatment Market Report Key Strengths

• 15 Years Castration-Resistant Prostate Cancer (CRPC) Market Forecast
• Global Coverage
• Castration-Resistant Prostate Cancer (CRPC) Epidemiology Segmentation
• Key Cross Competition

 

Castration-Resistant Prostate Cancer (CRPC) Treatment Market Report Assessment

• Present Practices in the Castration-Resistant Prostate Cancer (CRPC) Treatment Market
• Review of Investigational Castration-Resistant Prostate Cancer (CRPC) Drugs
• Attractiveness of the Castration-Resistant Prostate Cancer (CRPC) Drug Market
• Castration-Resistant Prostate Cancer (CRPC) Market Drivers
• Castration-Resistant Prostate Cancer (CRPC) Market Barriers
• SWOT
• Attribute Analysis

 

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the castration-resistant prostate cancer (CRPC) market based on the below-mentioned segments:

 

Global Castration-Resistant Prostate Cancer (CRPC) Market, By Therapy Type

• Hormonal Therapy
• Immunotherapy
• Chemotherapy
• Radiotherapy

 

Global Castration-Resistant Prostate Cancer (CRPC) Market, By Drug Class

• Antineoplastic
• Non-steroidal Antiandrogen
• Corticosteroids
• Microtubule Inhibitor
• Others

 

Global Castration-Resistant Prostate Cancer (CRPC) Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa